A life-threatening ruxolitinib discontinuation syndrome.

Lisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Tiziana Fanelli, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Srdan Verstovsek, Alessandro M. Vannucchi, JAK2V617F Complete Molecular Remission in Polycythemia vera/essential Thrombocythemia Patients Treated With Ruxolitinib Blood. ,vol. 125, pp. 3352- 3353 ,(2015) , 10.1182/BLOOD-2015-01-624536

Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson, Christy Finke, Emnet A. Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A. Belachew, Terra L. Lasho, Rhett P. Ketterling, Curtis A. Hanson, Alessandro Rambaldi, Guido Finazzi, Juergen Thiele, Tiziano Barbui, Animesh Pardanani, Alessandro M. Vannucchi, Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis Blood. ,vol. 124, pp. 2507- 2513 ,(2014) , 10.1182/BLOOD-2014-05-579136

Ross L. Levine, Martha Wadleigh, Jan Cools, Benjamin L. Ebert, Gerlinde Wernig, Brian J.P. Huntly, Titus J. Boggon, Iwona Wlodarska, Jennifer J. Clark, Sandra Moore, Jennifer Adelsperger, Sumin Koo, Jeffrey C. Lee, Stacey Gabriel, Thomas Mercher, Alan D’Andrea, Stefan Fröhling, Konstanze Döhner, Peter Marynen, Peter Vandenberghe, Ruben A. Mesa, Ayalew Tefferi, James D. Griffin, Michael J. Eck, William R. Sellers, Matthew Meyerson, Todd R. Golub, Stephanie J. Lee, D. Gary Gilliland, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. ,vol. 7, pp. 387- 397 ,(2005) , 10.1016/J.CCR.2005.03.023

Raajit Rampal, Fatima Al-Shahrour, Omar Abdel-Wahab, Jay P. Patel, Jean-Philippe Brunel, Craig H. Mermel, Adam J. Bass, Jennifer Pretz, Jihae Ahn, Todd Hricik, Outi Kilpivaara, Martha Wadleigh, Lambert Busque, D. Gary Gilliland, Todd R. Golub, Benjamin L. Ebert, Ross L. Levine, Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis Blood. ,vol. 123, ,(2014) , 10.1182/BLOOD-2014-02-554634

Tiziano Barbui, Guido Finazzi, Alessandra Carobbio, Juergen Thiele, Francesco Passamonti, Elisa Rumi, Marco Ruggeri, Francesco Rodeghiero, Maria Luigia Randi, Irene Bertozzi, Heinz Gisslinger, Veronika Buxhofer-Ausch, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Alessandro M. Vannucchi, Ayalew Tefferi, Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) Blood. ,vol. 120, pp. 5128- 5133 ,(2012) , 10.1182/BLOOD-2012-07-444067

Yan Beauverd, Kaveh Samii, Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation International Journal of Hematology. ,vol. 100, pp. 498- 501 ,(2014) , 10.1007/S12185-014-1628-5

Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Peggy A. Scherle, Eian Caulder, Xiaoming Wen, Yanlong Li, Paul Waeltz, Mark Rupar, Timothy Burn, Yvonne Lo, Jennifer Kelley, Maryanne Covington, Stacey Shepard, James D. Rodgers, Patrick Haley, Hagop Kantarjian, Jordan S. Fridman, Srdan Verstovsek, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. ,vol. 115, pp. 3109- 3117 ,(2010) , 10.1182/BLOOD-2009-04-214957

Ayalew Tefferi, Pathogenesis of Myelofibrosis With Myeloid Metaplasia Journal of Clinical Oncology. ,vol. 23, pp. 8520- 8530 ,(2005) , 10.1200/JCO.2004.00.9316

Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Paola Guglielmelli, Chiara Elena, Shui He, Nancy Contel, Bijoyesh Mookerjee, Victor Sandor, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi, A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea Cancer. ,vol. 120, pp. 513- 520 ,(2014) , 10.1002/CNCR.28441

Claire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richard Levy, Laurent Knoops, Francisco Cervantes, Alessandro M. Vannucchi, Tiziano Barbui, Giovanni Barosi, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine. ,vol. 366, pp. 787- 798 ,(2012) , 10.1056/NEJMOA1110556